Diclofenac sr (diclofenac) – happy family pharmacy
Sustained-Release Pain Relief for Arthritis and Inflammation – Buy Over The Counter
What is diclofenac sr?
Diclofenac SR is a sustained-release formulation of Diclofenac, a potent nonsteroidal anti-inflammatory drug that has been widely used in clinical practice for decades to manage pain, inflammation, and swelling associated with various musculoskeletal conditions. The SR designation stands for sustained release, indicating that the tablet is designed to release the active ingredient gradually over an extended period, typically twelve to twenty-four hours, allowing for once-daily or twice-daily dosing with relatively stable plasma drug levels. Diclofenac belongs to the phenylacetic acid derivative class of NSAIDs and is one of the most commonly prescribed anti-inflammatory medications globally, owing to its favorable balance of efficacy and tolerability. The medication exerts its therapeutic effects through non-selective inhibition of cyclooxygenase enzymes, specifically COX-1 and COX-2, which are responsible for the synthesis of prostaglandins, prostacyclin, and thromboxane from arachidonic acid. By reducing the production of these inflammatory mediators, diclofenac effectively relieves pain, reduces inflammation, and lowers fever. The sustained-release formulation of Diclofenac SR offers particular advantages for patients with chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis, where consistent, around-the-clock pain control is desirable. The prolonged release profile reduces the frequency of dosing, which improves patient adherence to therapy and minimizes the peaks and troughs in drug concentration that are associated with immediate-release formulations. This results in more consistent pain relief throughout the day and night, with fewer episodes of breakthrough pain that occur when analgesic drug levels fall below the therapeutic threshold. At Happy Family Pharmacy, we offer Diclofenac SR over the counter to provide patients with convenient access to this effective and versatile anti-inflammatory medication for the management of their pain and inflammatory conditions.
Pharmacological mechanism of diclofenac
The therapeutic action of diclofenac is mediated primarily through its potent inhibition of the cyclooxygenase enzymes, which are key catalysts in the conversion of arachidonic acid, a membrane phospholipid-derived fatty acid, into prostaglandins and related eicosanoids. Two distinct isoforms of the cyclooxygenase enzyme exist in human physiology, each with distinct tissue distributions, regulatory mechanisms, and physiological roles. COX-1 is constitutively expressed in most tissues and is responsible for the production of prostaglandins that maintain normal physiological functions, including the protection of the gastric mucosa from acid-induced injury by stimulating mucus and bicarbonate secretion, the regulation of renal blood flow and glomerular filtration, and the promotion of platelet aggregation through the synthesis of thromboxane A2. COX-2, in contrast, is primarily an inducible enzyme whose expression is upregulated in response to inflammatory stimuli such as cytokines, growth factors, and bacterial endotoxins. The prostaglandins produced by COX-2 at sites of inflammation mediate the cardinal signs of inflammation, namely pain, swelling, redness, and heat. Diclofenac is a non-selective COX inhibitor, meaning that it inhibits both COX-1 and COX-2 isoforms, though it exhibits approximately four-fold greater selectivity for COX-2 than for COX-1 at therapeutic concentrations. This relative COX-2 selectivity partially explains the anti-inflammatory efficacy of diclofenac and its intermediate gastrointestinal safety profile compared with other non-selective NSAIDs such as indomethacin and piroxicam. The inhibition of COX-2 reduces the production of pro-inflammatory prostaglandins at the site of tissue injury, decreasing the sensitization of peripheral nociceptors to pain-mediating substances such as bradykinin and histamine. This peripheral analgesic effect is complemented by a central analgesic effect mediated through the inhibition of prostaglandin synthesis in the spinal cord and brain. Diclofenac also appears to possess analgesic properties independent of its effects on prostaglandin synthesis, including inhibition of the lipoxygenase pathway and modulation of nitric oxide signaling pathways. The sustained-release formulation of diclofenac employs a specially designed matrix system that controls the rate at which the drug dissolves and is released into the gastrointestinal tract. Following oral administration, the tablet hydrates and forms a gel layer on its surface, through which the dissolved drug must diffuse to reach the gastrointestinal fluids. As the drug near the surface dissolves and is released, water gradually penetrates deeper into the matrix, dissolving the drug further within the tablet core. This process results in a relatively constant rate of drug release over an extended period, maintaining plasma concentrations within the therapeutic range for twelve to twenty-four hours and obviating the need for more frequent dosing.
Clinical indications for diclofenac sr
Diclofenac SR is indicated for the management of many conditions involving pain and inflammation, encompassing both acute and chronic musculoskeletal disorders and certain systemic inflammatory diseases. The most prevalent indication for sustained-release diclofenac is the symptomatic management of osteoarthritis, the most common form of arthritis, which involves the progressive degeneration of articular cartilage, subchondral bone remodeling, osteophyte formation, and synovial inflammation. Osteoarthritis most commonly affects the knees, hips, hands, and spine, causing chronic pain that is typically worse with weight-bearing activity and improves with rest. The sustained-release formulation is particularly well suited to osteoarthritis because it provides continuous pain relief that spans the daytime hours of activity and the nighttime hours of rest, reducing morning stiffness and improving sleep quality. Rheumatoid arthritis, a systemic autoimmune disease characterized by symmetric polyarthritis with joint pain, swelling, and progressive destruction, is another major indication for diclofenac therapy. While disease-modifying antirheumatic drugs such as methotrexate are the foundation of treatment for rheumatoid arthritis, NSAIDs including diclofenac SR play an important adjunctive role in controlling pain and inflammation, particularly during the period before DMARDs take effect or during disease flares. Ankylosing spondylitis, a chronic inflammatory arthritis primarily affecting the sacroiliac joints and the axial skeleton, is particularly responsive to NSAID therapy, and diclofenac is among the most effective agents for relieving the inflammatory back pain, morning stiffness, and restricted spinal mobility that characterize this condition. In some cases, continuous NSAID therapy may slow the radiographic progression of ankylosing spondylitis. Acute gouty arthritis, characterized by the sudden onset of severe pain, redness, and swelling in a single joint, most commonly the first metatarsophalangeal joint, can be treated effectively with high-dose diclofenac, though the immediate-release formulation is often preferred for its more rapid onset of action in this acute setting. Acute musculoskeletal injuries, including sprains, strains, contusions, and tendonitis, are responsive to the analgesic and anti-inflammatory effects of diclofenac. While acute therapy often begins with immediate-release formulations or topical preparations, sustained-release tablets may be used for ongoing management of pain during the healing phase. Postoperative pain management is another application of diclofenac, as NSAIDs reduce the requirement for opioid analgesics and their associated side effects. Dysmenorrhea, or painful menstrual periods, is driven by the release of prostaglandins from the endometrium, which cause uterine smooth muscle contraction, ischemia, and pain. Diclofenac is highly effective in relieving dysmenorrhea when initiated at the onset of symptoms or prophylactically before the anticipated start of menses. Renal colic, the severe flank pain caused by the passage of a kidney stone through the ureter, can be alleviated by NSAIDs including diclofenac, which reduce ureteral smooth muscle spasm and inflammation. Other conditions for which diclofenac may be used include dental pain, migraine headaches, bursitis, and tenosynovitis.
Dosing and administration of diclofenac sr
The dosing of Diclofenac SR should be individualized to the lowest effective dose for the shortest duration consistent with the patient’s treatment goals. For the management of osteoarthritis, the recommended dose of sustained-release diclofenac is one hundred milligrams administered once daily, which is the usual starting and maintenance dose for most patients. In some individuals, adequate symptom control may be achieved with a lower dose of seventy-five milligrams daily, while others may require the full one hundred milligram dose. The once-daily dosing regimen made possible by the sustained-release technology is convenient for patients and promotes adherence to therapy. For rheumatoid arthritis and ankylosing spondylitis, the recommended dose is typically one hundred milligrams once daily, with the option to increase to one hundred milligrams twice daily if the inflammatory burden is severe and the patient tolerates the medication well. The higher dosing range should only be used after careful consideration of the increased risk of adverse effects, particularly gastrointestinal, cardiovascular, and renal toxicities. The total daily dose of diclofenac should not exceed one hundred fifty milligrams in any patient, even those with the most severe inflammatory conditions. Diclofenac SR tablets should be swallowed whole with a full glass of water, and patients should be advised not to crush, chew, or break the tablets, as doing so would disrupt the sustained-release mechanism and result in rapid release and absorption of the entire dose, potentially leading to toxicity. The tablets should be taken with food or milk to minimize gastrointestinal irritation, as food does not affect the extent of absorption but may delay the time to peak concentration slightly. Patients should maintain an upright posture for at least fifteen to thirty minutes after taking the tablet to facilitate passage through the esophagus and to reduce the risk of esophageal irritation and ulceration. For elderly patients, those with low body weight, and those with mild to moderate renal or hepatic impairment, the lowest effective dose should be used, and careful monitoring for adverse effects is essential. The use of diclofenac in patients with severe renal impairment, defined as a creatinine clearance of less than thirty milliliters per minute, is generally contraindicated due to the risk of further deterioration of renal function. In patients with established cardiovascular disease or significant risk factors for cardiovascular disease, diclofenac should be used at the lowest effective dose for the shortest possible duration, and alternative analgesic options should be considered whenever feasible. Patients should be advised that the full analgesic effect of diclofenac may not be achieved for several days to a week of continuous therapy, particularly for inflammatory conditions where the reduction of synovial inflammation lags behind the achievement of therapeutic drug levels. If satisfactory pain relief is not achieved after two to three weeks of treatment at an adequate dose, the diagnosis should be reassessed, and alternative therapeutic approaches should be considered. The decision to continue long-term NSAID therapy should be re-evaluated at regular intervals, with periodic attempts to reduce the dose or discontinue the medication to determine whether the underlying condition has improved and whether ongoing therapy remains necessary.
Gastrointestinal side effects and management
The most common adverse effects of diclofenac involve the gastrointestinal system, reflecting important role of COX-1-derived prostaglandins in maintaining the integrity of the gastric and duodenal mucosa. The spectrum of gastrointestinal side effects ranges from mild, transient dyspepsia to life-threatening gastrointestinal bleeding, perforation, and obstruction. Dyspepsia, characterized by epigastric discomfort, burning, bloating, and nausea, is reported by ten to thirty percent of patients taking diclofenac. While dyspepsia is distressing and can interfere with medication adherence, its presence does not reliably predict the presence or absence of significant mucosal injury, and conversely, the absence of dyspepsia does not guarantee mucosal integrity. Many patients with endoscopically documented gastric or duodenal ulcers remain asymptomatic, and the first manifestation of NSAID-induced gastrointestinal injury may be a catastrophic bleed or perforation. Gastritis, erosive gastropathy, and peptic ulcer disease are consequences of the depletion of mucosal prostaglandins, which normally stimulate mucus and bicarbonate secretion, maintain mucosal blood flow, and promote epithelial restitution after injury. In the absence of these protective mechanisms, the gastric mucosa becomes vulnerable to injury from gastric acid, pepsin, and bile acids. The risk of serious gastrointestinal events, defined as bleeding, perforation, or clinically significant obstruction, increases with the dose and duration of diclofenac therapy, advanced age, a history of peptic ulcer disease or gastrointestinal bleeding, concurrent use of anticoagulants or antiplatelet agents, concurrent use of corticosteroids, smoking, and heavy alcohol consumption. The annual incidence of serious NSAID-induced gastrointestinal complications is approximately one to four percent in patients taking NSAIDs regularly, representing a significant public health burden. Strategies to mitigate gastrointestinal risk include the use of the lowest effective dose for the shortest possible duration, co-prescription of a proton pump inhibitor such as omeprazole, esomeprazole, pantoprazole, or lansoprazole to suppress gastric acid secretion, or the use of misoprostol, a synthetic prostaglandin E1 analog that replaces the depleted mucosal prostaglandins. Proton pump inhibitors are generally preferred because of their superior efficacy and tolerability compared with misoprostol, which commonly causes diarrhea and abdominal cramping. H2-receptor antagonists such as famotidine and ranitidine are less effective than PPIs in preventing NSAID-induced gastric ulcers but may provide adequate protection for patients at lower risk. Another approach is the use of a selective COX-2 inhibitor, which inhibits COX-2 while sparing COX-1, theoretically preserving gastroprotective prostaglandins while still providing anti-inflammatory efficacy. However, COX-2 selective agents are associated with an increased risk of cardiovascular thrombotic events, and the overall risk-benefit balance must be considered for each individual patient. Helicobacter pylori infection is an independent risk factor for peptic ulcer disease, and testing for this organism should be considered in patients with a history of ulcer disease who are being started on long-term NSAID therapy. Eradication of H. Pylori before initiating NSAID therapy reduces the risk of ulcer development during subsequent NSAID use. Patients taking diclofenac should be educated about the signs and symptoms of gastrointestinal bleeding, including black, tarry stools, vomit that resembles coffee grounds, severe abdominal pain, and symptoms of anemia such as fatigue, pallor, and shortness of breath on exertion. If any of these symptoms develop, the medication should be discontinued, and medical attention should be sought immediately. Routine laboratory monitoring, including a complete blood count to detect occult gastrointestinal blood loss and resultant iron deficiency anemia, should be performed periodically in patients on long-term diclofenac therapy.
Cardiovascular risk and diclofenac sr
Cardiovascular Warning: Diclofenac and other NSAIDs may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke. This risk increases with the duration of use and may occur early in treatment. Patients with cardiovascular disease or risk factors are at greater risk.
All NSAIDs, including diclofenac, carry a boxed warning from regulatory agencies regarding the increased risk of cardiovascular thrombotic events. The mechanism by which NSAIDs increase cardiovascular risk is related to the inhibition of COX-2 in the vascular endothelium, which reduces the production of prostacyclin, a prostaglandin that inhibits platelet aggregation, causes vasodilation, and opposes the pro-thrombotic effects of thromboxane A2, which is produced by COX-1 in platelets. When COX-2 is inhibited, prostacyclin production falls while thromboxane production continues unabated via COX-1, shifting the hemostatic balance toward a pro-thrombotic state. This pro-thrombotic milieu promotes platelet aggregation, vasoconstriction, and vascular smooth muscle proliferation, all of which contribute to the pathogenesis of acute coronary syndromes and ischemic strokes. Among the non-selective NSAIDs, diclofenac appears to be associated with a cardiovascular risk profile that is similar to that of COX-2 selective inhibitors and higher than that of naproxen. The risk of myocardial infarction and stroke is increased even with short-term use of NSAIDs, and the absolute risk increases with the dose and duration of therapy. Patients with established cardiovascular disease, including those with a history of myocardial infarction, coronary artery bypass grafting, stable angina, unstable angina, stroke, or transient ischemic attack, are at the highest risk and should generally avoid diclofenac and other NSAIDs unless no alternative analgesic options exist and the potential benefit clearly outweighs the cardiovascular risk. Patients with multiple cardiovascular risk factors, including hypertension, hyperlipidemia, diabetes mellitus, smoking, obesity, and a strong family history of premature cardiovascular disease, are also at elevated risk and should use diclofenac only after careful consideration of the risk-benefit ratio. Hypertension is both a risk factor for cardiovascular events and a potential adverse effect of NSAID therapy. Diclofenac can cause sodium and water retention, leading to a measurable increase in blood pressure, typically in the range of three to five millimeters of mercury, in both normotensive and hypertensive individuals. This effect can destabilize previously well-controlled blood pressure and increase the risk of cardiovascular events. Blood pressure should be monitored closely in all patients taking diclofenac, particularly during the initial weeks of therapy and after dose adjustments. Patients taking antihypertensive medications may require dose adjustments, as NSAIDs can attenuate the blood pressure-lowering effects of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and diuretics. Heart failure is another condition that can be precipitated or exacerbated by NSAID use, as the sodium and water retention induced by these agents increases intravascular volume and the workload of the heart. Patients with pre-existing heart failure, particularly those with reduced left ventricular ejection fraction, should avoid diclofenac if possible. The risk of cardiovascular events should be discussed with all patients before initiating diclofenac therapy, and patients should be educated about the signs and symptoms of myocardial infarction, including chest pain, shortness of breath, diaphoresis, nausea, and radiation of pain to the arm, jaw, or back, and stroke, including sudden weakness or numbness on one side of the body, facial droop, speech difficulty, visual disturbance, and loss of balance. Patients should be instructed to seek emergency medical attention immediately if any of these symptoms occur. The lowest effective dose of diclofenac should be used for the shortest duration necessary to control symptoms, and the ongoing need for therapy should be regularly reassessed. For patients who require long-term anti-inflammatory or analgesic therapy, consideration should be given to alternative treatments that carry a lower cardiovascular risk, or to the addition of low-dose aspirin for cardioprotection, though the combination of aspirin with A NSAID increases the risk of gastrointestinal bleeding and this risk must also be considered in the overall risk-benefit analysis.
Order Diclofenac SR today from Happy Family Pharmacy for reliable pain relief.
Buy Diclofenac SR (Diclofenac) Over The Counter at Happy Family Pharmacy
Genuine NSAID Medication – Fast Delivery – Affordable Prices
Renal effects and monitoring
The effects of diclofenac on renal function are an important consideration, particularly in patients who depend on prostaglandin-mediated compensatory mechanisms to maintain adequate renal perfusion. In the normal kidney under euvolemic conditions, prostaglandins play a relatively minor role in the regulation of renal blood flow and glomerular filtration. However, in states of reduced effective circulating volume, such as those caused by congestive heart failure, cirrhosis with ascites, nephrotic syndrome, volume depletion from diuretic use or gastrointestinal losses, and renal artery stenosis, renal perfusion becomes critically dependent on the vasodilatory effects of prostaglandins on the afferent arteriole. Under these conditions, inhibition of prostaglandin synthesis by diclofenac can precipitate acute kidney injury characterized by a rapid rise in serum creatinine, oliguria, sodium and water retention, and hyperkalemia. The acute renal effects of NSAIDs are generally reversible upon discontinuation of the offending agent, but they can be severe enough to require temporary dialysis in high-risk patients. In addition to these hemodynamically mediated effects, NSAIDs have been implicated in several other forms of renal injury. Acute interstitial nephritis, a hypersensitivity reaction characterized by infiltration of the renal interstitium with inflammatory cells, typically presents with acute kidney injury, often accompanied by fever, rash, eosinophilia, and eosinophiluria. Papillary necrosis, a chronic form of renal injury associated with long-term, high-dose NSAID use, can lead to progressive renal insufficiency and an increased risk of urinary tract infections and nephrolithiasis. Membranous nephropathy, a glomerular disease that presents with nephrotic-range proteinuria, has been associated with diclofenac use and may require discontinuation of the medication and immunosuppressive therapy for resolution. The risk of renal adverse effects is dose-dependent and increases with the duration of therapy. Patients at highest risk include those with pre-existing renal impairment, advanced age, diabetes mellitus, hypertension, heart failure, liver disease, and those taking concomitant medications that affect renal function, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, and calcineurin inhibitors. Before initiating diclofenac therapy, renal function should be assessed with measurement of serum creatinine, estimated glomerular filtration rate, and urinalysis. During chronic therapy, renal function should be monitored periodically, with the frequency determined by the patient’s baseline renal function, age, comorbidities, and concomitant medications. Any significant increase in serum creatinine, decrease in estimated glomerular filtration rate, or development of proteinuria should prompt reassessment of the need for continued NSAID therapy and consideration of alternative analgesic or anti-inflammatory strategies. Patients should be counseled to maintain adequate hydration while taking diclofenac, particularly during periods of hot weather, strenuous exercise, or intercurrent illness that may lead to volume depletion. They should also be educated about the signs of fluid retention, including swelling of the ankles, feet, or hands, rapid weight gain, and shortness of breath, and should report these symptoms to their healthcare provider. It is advisable to avoid the concurrent use of other potentially nephrotoxic medications, including aminoglycoside antibiotics, amphotericin B, and intravenous contrast dye, in patients taking diclofenac, and such combinations should only be undertaken when absolutely necessary and with close monitoring of renal function. If acute kidney injury develops in a patient taking diclofenac, the medication should be discontinued immediately, and supportive care should be provided, including optimization of volume status and avoidance of other nephrotoxic insults.
Drug interactions with diclofenac sr
Diclofenac participates in various clinically significant drug interactions that must be considered to ensure the safe and effective use of this medication. The interaction with anticoagulant medications, including warfarin and the direct oral anticoagulants such as rivaroxaban, apixaban, and dabigatran, is among the most consequential. NSAIDs inhibit platelet aggregation by blocking COX-1-mediated thromboxane A2 production, thereby producing a qualitative platelet defect that impairs primary hemostasis. When combined with anticoagulants that target the coagulation cascade, the risk of bleeding, particularly gastrointestinal bleeding, is increased. The combination of A NSAID with warfarin increases the risk of gastrointestinal bleeding by three to six-fold compared with warfarin alone, a finding that has been consistently replicated across multiple observational studies and database analyses. If the combination of diclofenac and an anticoagulant is deemed necessary, patients should be monitored closely for signs of bleeding, and the international normalized ratio should be checked more frequently in those taking warfarin. Prophylactic gastroprotection with a proton pump inhibitor should be strongly considered. Antiplatelet agents, including aspirin and clopidogrel, also interact with diclofenac to increase bleeding risk through additive effects on platelet function. Low-dose aspirin is commonly used for cardioprotection, and many patients taking NSAIDs for arthritis are also candidates for aspirin therapy based on their cardiovascular risk profile. The combination of diclofenac and aspirin not only increases gastrointestinal bleeding risk and compromises the cardioprotective effect of aspirin if diclofenac is administered before aspirin, as NSAIDs can block the access of aspirin to the COX-1 binding site within the platelet. If both medications are needed, aspirin should be taken at least two hours before diclofenac. Other NSAIDs, including both prescription and over-the-counter agents such as ibuprofen, naproxen, and meloxicam, should not be used concurrently with diclofenac, as the combined anti-inflammatory and analgesic effects are not additive, but the risk of gastrointestinal, cardiovascular, and renal toxicity is increased. Antihypertensive medications, including ACE inhibitors, angiotensin receptor blockers, beta-blockers, and diuretics, may be rendered less effective when co-administered with diclofenac. The pressor effect of NSAIDs, mediated by sodium and water retention and inhibition of vasodilatory prostaglandins, can lead to a measurable increase in blood pressure, offsetting the therapeutic effect of antihypertensive drugs. Blood pressure should be monitored more frequently when initiating, discontinuing, or adjusting the dose of diclofenac in patients taking antihypertensive medications. Lithium is a mood stabilizer with a narrow therapeutic index that is excreted primarily by the kidneys. NSAIDs, including diclofenac, can reduce renal lithium clearance, leading to elevated serum lithium concentrations and potentially lithium toxicity, which manifests with tremor, ataxia, confusion, and in severe cases, seizures and coma. Serum lithium levels should be monitored closely and the lithium dose may need to be reduced when diclofenac is initiated, and conversely, the lithium dose may need to be increased when diclofenac is discontinued. Methotrexate, particularly at the high doses used for cancer chemotherapy, can have its renal clearance reduced by NSAIDs, leading to elevated methotrexate levels and an increased risk of severe methotrexate toxicity, including myelosuppression, mucositis, and hepatotoxicity. This interaction is primarily a concern with moderate-to-high dose methotrexate used in oncology, and less so with the low doses used for rheumatoid arthritis, though caution is still advised. Cyclosporine and tacrolimus, calcineurin inhibitors used for immunosuppression in transplant recipients and for the treatment of autoimmune diseases, can have their nephrotoxic effects potentiated by concurrent NSAID use, as both drug classes reduce renal blood flow through complementary mechanisms. Renal function should be monitored carefully in patients receiving this combination. Diuretics may be less effective when co-administered with diclofenac, as the sodium-retaining effects of the NSAID oppose the natriuretic effects of the diuretic, potentially leading to fluid retention and worsening of heart failure. This interaction is particularly relevant for loop diuretics such as furosemide and thiazide diuretics such as hydrochlorothiazide. Aminoglycoside antibiotics may have their nephrotoxic and ototoxic effects exacerbated by concurrent NSAID use, and this combination should be avoided when possible. Given the extensive list of potential drug interactions, patients should provide their healthcare providers and pharmacists with a complete list of all medications they are taking, including prescription drugs, over-the-counter preparations, herbal supplements, and vitamins, to allow for a thorough assessment of potential interactions before initiating diclofenac therapy and throughout the course of treatment.
Geriatric and special population considerations
The use of Diclofenac SR in elderly patients, those over sixty-five years of age, requires particular caution due to the increased susceptibility of this population to the adverse effects of NSAIDs. Advancing age is associated with a progressive decline in renal function, even in the absence of overt renal disease, as the glomerular filtration rate falls by approximately one milliliter per minute per year after the age of forty. This age-related reduction in renal reserve makes older patients more vulnerable to NSAID-induced acute kidney injury. The prevalence of comorbid conditions that increase the risk of adverse NSAID effects, including hypertension, heart failure, diabetes mellitus, and atherosclerotic cardiovascular disease, increases with age. Polypharmacy, which is common in the geriatric population, increases the likelihood of drug-drug interactions that can amplify the toxicity of diclofenac. The use of multiple medications that affect hemostasis, including anticoagulants and antiplatelet agents prescribed for atrial fibrillation, venous thromboembolism, and coronary artery disease, is particularly prevalent in older adults and elevates the risk of gastrointestinal bleeding when combined with A NSAID. The pharmacokinetics of diclofenac are altered in the elderly, with reduced hepatic metabolism and renal clearance leading to higher plasma drug concentrations for a given dose and prolongation of the elimination half-life. For all of these reasons, the American Geriatrics Society Beers Criteria for Potentially Inappropriate Medication Use in Older Adults lists chronic NSAID use as a medication to be used with extreme caution, and it is recommended that alternative analgesic options be considered first-line in this population. When diclofenac is used in elderly patients, the lowest effective dose should be prescribed for the shortest possible duration, and renal function, blood pressure, and complete blood counts should be monitored at regular intervals. Proton pump inhibitor gastroprotection should be strongly considered for all older adults taking NSAIDs chronically. In pregnant women, diclofenac should be avoided during the third trimester, as NSAIDs can cause premature closure of the fetal ductus arteriosus, a vascular connection between the pulmonary artery and the aorta that is essential for fetal circulation but must close after birth to allow the transition to postnatal circulatory patterns. Premature closure in utero can lead to persistent pulmonary hypertension of the newborn, a serious and potentially fatal condition. NSAID use in late pregnancy is also associated with oligohydramnios, or low amniotic fluid volume, due to reduced fetal urine production, and with prolongation of gestation and labor due to inhibition of prostaglandin-mediated uterine contractions. The use of diclofenac in the first and second trimesters should be limited to situations where the potential benefit clearly outweighs the potential risk to the developing fetus. In lactating women, diclofenac passes into breast milk in very small amounts that are unlikely to cause harm to the nursing infant, and it is considered compatible with breastfeeding by the American Academy of Pediatrics. However, the infant should be observed for signs of gastrointestinal disturbance or bleeding. In patients with hepatic impairment, diclofenac should be used with caution, as the drug is metabolized in the liver. Significant liver disease can reduce the clearance of diclofenac and increase the risk of hepatotoxicity, which is a rare but well-recognized adverse effect of the drug. Liver function tests should be monitored periodically in all patients on chronic diclofenac therapy, with increased frequency in those with pre-existing liver disease or risk factors for hepatotoxicity. The development of elevated transaminases, particularly if accompanied by clinical symptoms of hepatitis such as jaundice, right upper quadrant pain, nausea, and fatigue, should prompt immediate discontinuation of the medication. For patients with a history of aspirin-sensitive asthma, diclofenac and other NSAIDs can precipitate life-threatening bronchospasm, and these agents should be avoided altogether in this population. Patients with systemic lupus erythematosus may be at increased risk for aseptic meningitis and hepatotoxicity from NSAIDs, and diclofenac should be used with caution in this population.
Get sustained pain relief with Diclofenac SR from Happy Family Store – order online now.